Recently, the “2026 China Pharmaceutical Innovation 100 Conference” was grandly held, during which the annual “Top 100 Chinese Pharmaceutical Innovative Enterprises” (the “Innovation Top 100”) ranking was officially unveiled. Backed by years of sustained and steady R&D investment, differentiated innovative pipeline, robust clinical translation capabilities, and strong commercialization potential, Alphamab Oncology has once again been named to the ranking, reaffirming its pivotal position in China’s biopharmaceutical innovation sector and earning authoritative recognition from the industry for its core innovation strength.
As a highly authoritative, professional and prestigious ranking in the pharmaceutical industry, the “Top 100 Chinese Pharmaceutical Innovative Enterprises” is jointly launched by Healthcare Executive and Clarivate. The ranking is based on the Cortellis data intelligence platform, which covers the entire drug development lifecycle, and adopts a “three‑dimension, four‑indicator” evaluation system. It comprehensively assesses enterprises across three dimensions—innovation foundation, innovation process, and innovation outcomes—using four key metrics: the number of granted core patents for innovative drugs, the number of granted peripheral patents for innovative drugs, the number of clinical trials conducted, and the number of innovative drugs approved and commercialized. The selected enterprises represent the backbone of China’s pharmaceutical innovation landscape and serve as industry benchmarks with a mature innovation ecosystem and robust growth momentum.
With over a decade of deep dedication to the field of oncology biopharmaceutical innovation, Alphamab Oncology has consistently focused on unmet clinical needs and remained committed to original innovation, building core technology platforms with global competitiveness. Among them, its ADC technology platform stands out with advantages such as precise targeting, potent payloads, and excellent stability, effectively addressing industry pain points including high off‑target toxicity, insufficient stability, and limited indication scope seen in traditional ADC drugs. It has achieved key technological breakthroughs in safety, efficacy, and broad‑spectrum applicability, efficiently enabling the development of multiple innovative drugs across various solid tumor types, thereby providing a solid technical foundation for precision oncology therapy.
Leveraging its proprietary technology platforms, Alphamab Oncology has built a highly competitive innovative product pipeline. Its core ADC candidates, JSKN003 and JSKN016, focus on multiple refractory and recurrent solid tumors and have demonstrated breakthrough clinical results in breast cancer, lung cancer, gynecological tumors and gastrointestinal tumors, offering new treatment options for patients with advanced malignancies. Meanwhile, the company continues to iterate its ADC technology, refining and upgrading linkers, payloads, antibody screening, and other aspects, while also introducing formulation innovations such as subcutaneous injections, continuously generating next‑generation differentiated ADC candidates and further consolidating its leading position in the field of innovative biologics, particularly in ADCs.
In terms of R&D translation and industrialization, Alphamab Oncology has built a complete innovation value chain covering drug discovery, clinical development, and large‑scale manufacturing. Through years of sustained R&D investment, efficient clinical trial execution, and a rigorous quality management system, the company has successfully obtained market approval for two proprietary innovative drugs: the single‑domain antibody KN035 (Envafolimab, the world’s first subcutaneously injected PD‑(L)1 inhibitor) and the bispecific antibody KN026 (Anbenitamab, the first domestically developed HER2 bispecific antibody approved for marketing in China). These products have filled gaps in domestic clinical treatment options, delivered tangible benefits to a large number of cancer patients, and contributed to the high‑quality development of the biopharmaceutical industry. This inclusion in the Top 100 ranking constitutes comprehensive industry recognition of the company’s innovation achievements, technological strength, and growth potential.
Looking ahead, Alphamab Oncology will remain deeply committed to original innovation, accelerate the clinical development and market launch of its core pipeline products, and continuously push the boundaries of biopharmaceutical technology. Guided by clinical value, the company will support the industrial upgrading of China’s pharmaceutical innovation ecosystem and contribute more to safeguarding people’s lives and health.
About Alphamab Oncology
Alphamab Oncology (Stock Code: 9966.HK) is an innovative biopharmaceutical company focused on oncology. Leveraging proprietary platforms-including single-domain antibodies, bispecific antibodies, glycan-specific conjugation, linker-payloads, dual-payload ADCs, and high-concentration subcutaneous formulations, the Company has built a differentiated and globally competitive pipeline, covering cutting-edge candidates in ADCs, bispecific antibodies, and single-domain antibodies.
Two products have received market approval: Envafolimab (KN035, brand name: 恩维达®), the world's first subcutaneously injected PD-(L)1 inhibitor, offering greater convenience and accessibility in cancer treatment; and Anbenitamab (KN026, brand name: 恩尼妥®), the first domestically developed HER2 bispecific antibody approved for marketing in China, redefining the standard of treatment for second‑line HER2‑positive gastric cancer. Six bispecific ADC, dual-payload ADC candidates have entered clinical stages, and next-generation ADC pipelines are advancing rapidly. The Company has established strategic partnerships with organizations including CSPC, ArriVent, and Glenmark, covering both product development and technology platforms.
Our overarching mission is to make cancer manageable and curable by addressing unmet clinical needs in oncology. Alphamab Oncology is continuously dedicated to the development of effective, safe, and globally competitive anti-tumor drugs, enabling patients to achieve long-term, high-quality survival and delivering China-innovated cancer therapies to benefit patients worldwide.
Alphamab Oncology Forward-Looking Statements
This press release contains statements related to our future business，financial performance and future events involving Alphamab Oncology that may constitute forward-looking statements. These statements include projections and estimates and relevant assumptions, statements regarding plans and expectations and statements regarding future activities, operations and performance. These statements may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," or words of similar meaning. Such statements are based on the certain assumptions of Alphamab Oncology’s management and business operations, which are subject to various risks and uncertainties, including but not limited to political, economic, legal and business environment. The actual results, performance or achievements of Alphamab Oncology may (negatively or positively) vary materially from those described explicitly or implicitly in the relevant forward-looking statements. Unless otherwise required by applicable laws, Alphamab Oncology does not undertake obligation to publicly update any forward-looking statement nor liability for the failure to materialize such forward-looking statements, whether because of new information, future events or otherwise.
Pharmaceutical Information Statements
Alphamab Oncology does not recommend the clinical use of any already approved or under-development drugs/indications. Any information contained in this press release should not be regarded as any drug application, promotion or advertisement.
